|
業務類別
|
Biotechnology |
|
業務概覽
|
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV). |
| 公司地址
| 225 Franklin Street, Suite 2100, Boston, MA, USA, 02110 |
| 電話號碼
| +1 857 284-8891 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.ateapharma.com |
| 員工數量
| 56 |
| Ms. Andrea J. Corcoran |
Chief Financial Officer, Executive Vice President, Legal and Secretary |
美元 533.52K |
29/04/2025 |
| Dr. Jean-Pierre Sommadossi,PhD |
President, Chief Executive Officer and Chairman of the Board |
美元 703.49K |
29/04/2025 |
| Mr. Wayne Foster |
Executive Vice President, Finance and Chief Accounting Officer |
-- |
29/04/2025 |
| Dr. Janet Hammond, M.D.,PhD |
Chief Development Officer |
美元 573.68K |
29/04/2025 |
| Dr. Maria Arantxa Horga, M.D. |
Chief Medical Officer |
美元 508.39K |
29/04/2025 |
| Mr. John Vavricka |
Chief Commercial Officer |
美元 430.26K |
29/04/2025 |
|
|
| Dr. Howard Berman, PhD |
Director |
17/04/2025 |
| Mr. Franklin M. Berger, C.F.A. |
Lead Independent Director |
29/04/2025 |
| Dr. Jean-Pierre Sommadossi,PhD |
President, Chief Executive Officer and Chairman of the Board |
29/04/2025 |
| Dr. Bruce Polsky, M.D. |
Independent Director |
29/04/2025 |
| Ms. Barbara G. Duncan |
Independent Director |
29/04/2025 |
| Mr. Bruno Lucidi |
Independent Director |
29/04/2025 |
| Dr. Polly A. Murphy, D.V.M.,PhD |
Independent Director |
29/04/2025 |
| Dr. Jerome M. Adams, M.D. |
Independent Director |
29/04/2025 |
| Mr. Arthur Kirsch |
Director |
24/02/2025 |
|
|
|
|
